​

Funding Round

Post-IPO Equity - Genkyotex

Post-IPO Equity - Genkyotex

Investment Firm

Overview

Genkyotex develops innovative drugs to block the NOX enzymes that produce oxygen radicals.

Announced Date

Jan 07, 2015

Funding Type

Post Ipo Equity

Highlights

Location

Switzerland, Europe

Social

Investor Lead

Neomed Management

Neomed Management

Neomed Management is a early_stage_venture and late_stage_venture and private_equity and venture firm.

Participant Investors

6

Investor Name
Participant InvestorBioMedPartners
Participant InvestorVesalius Biocapital Partners
Participant InvestorNeomed Management
Participant InvestorVI Partners
Participant InvestorAndera Partners

Round Details and Background

Genkyotex raised $19742206 on 2015-01-07 in Post-IPO Equity

Genkyotex develops innovative drugs to block the NOX enzymes that produce oxygen radicals.

Company Funding History

8

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jul 09, 2012
Series C - Genkyotex
4-25.6M
May 24, 2011
Series C - Genkyotex
5-20.4M
Jan 30, 2006
Seed Round - Genkyotex
1-1.6M
May 05, 2008
Series A - Genkyotex
1-4.0M

Recent Activity

There is no recent news or activity for this profile.